Braxia Scientific Corp. (BRAXF)
USD 0.0
(-9.09%)
USD 0.0
(-9.09%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 7.65 Million CAD | 3.56% |
| 2022 | 3.87 Million CAD | -50.13% |
| 2021 | 7.77 Million CAD | 4655.65% |
| 2020 | 163.52 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 656.07 Thousand CAD | -48.89% |
| 2024 Q3 | 532.44 Thousand CAD | 300.88% |
| 2024 Q2 | 264.2 Thousand CAD | -59.73% |
| 2023 Q1 | 508.78 Thousand CAD | -59.18% |
| 2023 FY | 4.01 Million CAD | 3.56% |
| 2023 Q4 | 1.28 Million CAD | -13.02% |
| 2023 Q3 | 1.47 Million CAD | 97.09% |
| 2023 Q2 | 748.73 Thousand CAD | 47.16% |
| 2022 FY | 3.87 Million CAD | -50.13% |
| 2022 Q2 | 658.72 Thousand CAD | -2.47% |
| 2022 Q1 | 675.41 Thousand CAD | -68.96% |
| 2022 Q3 | 1.29 Million CAD | 96.92% |
| 2022 Q4 | 1.24 Million CAD | -3.9% |
| 2021 FY | 7.77 Million CAD | 4655.65% |
| 2021 Q2 | 2.05 Million CAD | -59.11% |
| 2021 Q1 | 5.03 Million CAD | 81.0% |
| 2021 Q3 | 1.52 Million CAD | -25.73% |
| 2021 Q4 | 2.17 Million CAD | 42.44% |
| 2020 Q4 | 2.77 Million CAD | 1808.58% |
| 2020 FY | 163.52 Thousand CAD | 0.0% |
| 2020 Q3 | 145.61 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 91.183% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -55.592% |
| SQZ Biotechnologies Company | 85.61 Million USD | 91.063% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 74.108% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 79.461% |
| Mesoblast Limited | 5.9 Million USD | -29.649% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -409.48% |
| Genus plc | 147.7 Million USD | 94.819% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 12.841% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -470.378% |
| Marizyme, Inc. | 19.23 Million USD | 60.229% |
| ContraFect Corporation | 56.88 Million USD | 86.549% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 8.24% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -73.564% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -417.455% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -162.389% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -174.226% |
| MultiCell Technologies, Inc. | 567.42 USD | -1348438.649% |
| Accustem Sciences Inc. | 3.74 Million USD | -104.245% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 91.097% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1338.426% |
| Q BioMed Inc. | 3.43 Million USD | -122.657% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 69.04% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1864.206% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -191.22% |
| Biomind Labs Inc. | 994.18 Thousand USD | -669.666% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 96.607% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -13.901% |
| Skye Bioscience, Inc. | 13.54 Million USD | 43.518% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -273.498% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 30707.512% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -51.761% |
| IMV Inc. | 37.7 Million USD | 79.708% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 52.206% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -316.974% |
| GB Sciences, Inc. | 1.42 Million USD | -438.672% |
| Alpha Cognition Inc. | 9.7 Million USD | 21.16% |
| HST Global, Inc. | 140.9 Thousand USD | -5330.446% |
| CSL Limited | 3.44 Billion USD | 99.778% |
| Halberd Corporation | 74.84 Thousand USD | -10124.043% |
| Enzolytics Inc. | 2.17 Million USD | -251.083% |
| Resverlogix Corp. | 12.71 Million USD | 39.806% |
| Affymax, Inc. | 39.38 Million USD | 80.572% |
| SYBLEU INC | 160.87 Thousand USD | -4656.383% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -109.6% |
| argenx SE | 1.53 Billion USD | 99.501% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 86.678% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -632.939% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -384.494% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -124.726% |
| AVAX Technologies, Inc. | 7.31 Million USD | -4.673% |
| Zenith Capital Corp. | 8.94 Million USD | 14.437% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.073% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -43823.299% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -211.645% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -4361.502% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 92.297% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -334.845% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -288.02% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -310.427% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 29.586% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -298.347% |
| BioStem Technologies, Inc. | 22.97 Million USD | 66.694% |
| ONE Bio Corp. | 6.44 Million USD | -18.746% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -4116.259% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -472.989% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -580.221% |
| Agentix Corp. | 1.37 Million USD | -457.816% |
| LadRx Corporation | 3.81 Million USD | -100.742% |
| Cell Source, Inc. | 4.32 Million USD | -76.908% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1741.7% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -728.565% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -728.565% |
| NovAccess Global Inc. | 2.46 Million USD | -210.199% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -218.174% |
| Itoco Inc. | 919.14 Thousand USD | -732.501% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -80.536% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -583.814% |
| Kadimastem Ltd | 2.41 Million USD | -217.491% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -2823.622% |
| CytoDyn Inc. | 18.05 Million USD | 57.626% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -30301.995% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1279.845% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -3376.894% |
| Qrons Inc. | 643.67 Thousand USD | -1088.776% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -438.944% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -243.152% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1052.391% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -321.285% |
| International Stem Cell Corporation | 5.27 Million USD | -45.169% |
| Bioxytran, Inc. | 3.82 Million USD | -100.303% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -14435.69% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -37514.305% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 78.901% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -372.922% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -939.89% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -145.962% |
| Neutra Corp. | 243.82 Thousand USD | -3038.318% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 56.167% |
| PureTech Health plc | 144.59 Million USD | 94.708% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 62.655% |
| IXICO plc | 4.7 Million USD | -62.564% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 13.017% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 93.501% |
| CSL Limited | 3.89 Billion USD | 99.803% |
| Cellectis S.A. | 97.32 Million USD | 92.137% |